Germany’s Bayer has announced encouraging results from the ongoing global Phase I first-in-human dose-escalation PAnTHa study of 225Ac-PSMA-Trillium, a targeted alpha therapy in advanced metastatic ca ...

By combining imaging and therapy in one targeted approach, researchers hope to select patients who will benefit from the targeted radiation and strike tumors more accurately, while overcoming the ...

A new study has revealed a promising new approach to curb the spread of triple-negative breast cancer, one of the most ...

Cabozantinib is presented as an emerging option with activity across extrapancreatic neuroendocrine tumors. Dr Lieu highlights its distinct mechanism of action and discusses how it expands treatment ...

Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of ...

GRAND RAPIDS, Mich. — 3.3 million American men live with prostate cancer, according to Zero Prostate Cancer. That makes it the most commonly diagnosed cancer for men in the U.S. There is a fairly new ...

However, most new metastases were treated with repeated stereotactic radiation or did not require treatment. In addition, only 3.2% of patients had a recurrence in a tumor treated with stereotactic ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today initiation of a Phase I clinical trial with 225 Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed to ...

A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, ...